20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T7512 | BMS-191011 | BMS-A | Potassium Channel |
BMS-191011 (BMS-A) is an activator of large-conductance calcium-activated potassium (BKCa) channels ,effective in stroke models | |||
T8542 | BMS-345541 hydrochloride | IκB/IKK | |
BMS-345541 hydrochloride is a selective IKK inhibitor (IKK2 and IKK1 with IC50 of 0.3 μM and 4 μM,respectively). | |||
T30520 | BMS-394136 | BMS394136,BMS 394136,BMS394136;UNII-M694U7167K | Potassium Channel |
BMS-394136 (BMS 394136) is a KV1.5 antagonist for the treatment of cardiovascular diseases such as arrhythmias and atrial fibrillation. | |||
T3462 | BMS-582949 hydrochloride | BMS-582949 HCl | p38 MAPK , Autophagy |
The BMS-582949 hydrochloride (BMS-582949 HCl) is a highly specific p38α MAPK inhibitor (IC50: 13 nM). | |||
T21790 | BMS 182874 hydrochloride | Endothelin Receptor | |
BMS 182874 hydrochloride is a nonpeptide endothelin (El) receptor antagonist. | |||
T22277L | BMS-P5 free base | PAD | |
BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor. BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Administration of BMS-... | |||
T22192 | BMS 195614 | BMS614 | Retinoid Receptor |
BMS 195614 (BMS614) is a selective RARα antagonist. BMS 195614 can bind to the RARα subunit. | |||
T6249 | Avagacestat | BMS-708163 | Gamma-secretase |
Avagacestat (BMS-708163) (BMS-708163) is a potent, selective, orally bioavailable γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM, demonstrating a 193-fold selectivity against Notch. Phase 2. | |||
T2699 | BMS 777607 | BMS777607,BMS-777607,BMS 817378 | c-Met/HGFR , TAM Receptor |
BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3 (IC50: 3.9/1.1/1.8/4.3 nM). BMS-777607 has been investigated for the basic science of Malignant Solid Tumour. | |||
T2610L | BMS-599626 2HCL(714971-09-2 Free base) | BMS 599626 dihydrochloride,BMS-599626 2HCL(714971-09-2 Free base),AC480 2HCl | HER |
BMS-599626 2HCL (AC480 2HCl) is a BMS-599626 derivative. BMS-599626 is an orally available and selective dual inhibitor of HER1 and HER2 with IC50s of 20 and 30 nM, respectively. BMS-599626 inhibits tumor cell proliferat... | |||
T2419 | BMS-794833 | VEGFR , c-Met/HGFR | |
BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378. | |||
T71394 | BMS-823778 | ||
BMS-823778 is an orally available potent and selective inhibitor of 11-β-hydroxysteroid-dehydrogenase 1 (11βHSD-1). BMS-823778 is a potential therapeutic agent for type 2 diabetes mellitus (T2DM). | |||
T8470 | BMS-1001 | PD-1/PD-L1 | |
BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay). | |||
T3495 | Tasimelteon | VEC-162,BMS-214778 | Melatonin Receptor , MT Receptor |
Tasimelteon (BMS-214778) is a melatonin receptor agonist that is used for the treatment of non-24 hour sleep-wake disorder in blind individuals. | |||
T39654 | Afimetoran | BMS-986256 | TLR |
Afimetoran (BMS-986256) is a toll-like receptor antagonist. Afimetoran can be used in the research of inflammatory and autoimmune diseases. | |||
T8326 | BMS-2 | VEGFR , FLT , c-Met/HGFR | |
BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor. | |||
T14676 | BMS-688521 | Integrin | |
BMS-688521 BMS-688521 is an orally active and potent inhibitor of LFA-1/ICAM interaction, a small molecule antagonist of leukocyte function-associated antigen-1 (LFA-1), with potential anti-inflammatory activity. | |||
T14681 | BMS-935177 | BTK | |
BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM. | |||
T60052 | BMS-905 | TLR | |
BMS-905 is a potent dual inhibitors of TLR7 and TLR8 with good selectivity against TLR9 and other family members. BMS-905 can be used in studies about the treatment of diseases such as psoriasis, arthritis, and lupus. | |||
T21714 | BMS453 | BMS 453,BMS-189453 | Retinoid Receptor |
BMS453 (BMS-189453), a synthetic retinoid, is a potent and selective agonist of RARβ and a potent testicular toxin. BMS453 inhibits breast cell growth predominantly through the induction of active TGFβ. |